Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
06 nov. 2023 08h00 HE
|
Aclarion, Inc.
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian...
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
25 oct. 2023 08h30 HE
|
Aclarion, Inc.
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George...
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
23 oct. 2023 07h00 HE
|
Aclarion, Inc.
Partnership aims to include Aclarion’s Nociscan surgical decisioning technology within ATEC’s AlphaInformatiX platform to better inform spine surgery ATEC is a medical device company dedicated to...
Aclarion Provides Updated Investor Presentation and Corporate Update
02 oct. 2023 08h00 HE
|
Aclarion, Inc.
Aclarion is steadily executing on a proven path toward standard of care. Ten prominent Key Opinion Leader (KOL) surgeons have formally engaged to partner with the company to drive market traction and...
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
25 août 2023 16h10 HE
|
Aclarion, Inc.
BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
08 juin 2023 07h30 HE
|
Aclarion, Inc.
Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually. The International Society for the Advancement...
Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
23 mai 2023 07h30 HE
|
Aclarion, Inc.
Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy Aclarion to Participate in...
Aclarion, Inc. Announces Delayed 10-Q Filing
23 mai 2023 07h00 HE
|
Aclarion, Inc.
BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
19 mai 2023 07h30 HE
|
Aclarion, Inc.
Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of...
Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain
02 mai 2023 07h00 HE
|
Aclarion, Inc.
Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market,...